Webinar: Targeted Protein Degradation (TPD) 鈥� The Hidden Treasure
脺ber das Live Webinar
听
| Titel: | 鈥淭argeted Protein Degradation (TPD) 鈥� The Hidden Treasure鈥� |
| 听Datum | Uhrzeit | Dauer: | Part 1:听May 7, 2024听 听|听 听4pm CEST / 7am PDT / 8am EDT听 听|听 听30 Minuten Part 2: May 14, 2024听 听|听 听4pm CEST / 7am PDT / 8am EDT听 听| 30 Minuten |
| Speakers | Dr. Helmut Buschmann (性视界 Chemicals), Dr. Anil Argarwal (性视界 Chemicals) |
听
Diese Webinar-Serie (Teil 1 + Teil 2) besch盲ftigt sich mit den neuesten Fortschritten in der Synthese von gezielten Proteindegradierern und erforscht modernste Techniken und Methoden, die die Zukunft therapeutischer Interventionen pr盲gen.
F眉hrende Experten diskutieren innovative Ans盲tze in der Gestaltung und Synthese von PROTACs und molekularen Klebstoffen, beleuchten zentrale Herausforderungen im Bereich und pr盲sentieren aktuelle Durchbr眉che, die die Behandlung komplexer Krankheiten revolutionieren k枚nnten.
Die Teilnehmer werden Einblicke in die sich entwickelnde Landschaft der gezielten Proteindegradation gewinnen, mit einem Schwerpunkt auf den Synthesestrategien, die klinische Anwendungen und therapeutische Wirksamkeit vorantreiben.
Speaker听 1) Dr. Helmut Buschmann 鈥� Chief Scientific Advisor
Helmut holds a PhD from the RWTH Aachen, Germany. After positions hold at Gr眉nenthal GmbH (Aachen), Laboratorius Dr. Esteve S.A. (Barcelona) and SAVIRA Pharmaceuticals GmbH (Vienna) he is now Head of Chemistry, Pharmaceutical Development and Patents at AiCuris GmbH (Wuppertal) and managing director of Research, Development & Consultancy GmbH (Vienna). As a result of his research activities more than 15 NCEs within different therapeutic areas have entered the clinical phase (e.g. Rosonabant, Cizorlitine, Dulopetine, Axamadol). Some of them have reached clinical phase III or are marketed (e.g. Tapentadol: Nucynta庐 Palexia庐,the first co-crystal of 2 APIs Tramadol and Celecoxib Seglentis庐).
He has authored and co-authored more than 150 scientific and peer reviewed publications, is named as lead inventor in more than 250 patent families and has edited five books in the field of drug discovery and development.听In 2014, he was awarded with the IUPAC-Richter Price for the discovery of the pain killer Tapentadol, which is marketed word-wide as Palexia庐 (Europe) and Nucynta庐 (US and Canada).
His research interests are drug impurities and the systematic recording of degradation pathways. He authored one of the first publications describing potential root causes for nitrosamine contamination. Since this time he was invited to several national and international congresses and is consulted as an expert in this field by academic institutes, pharmaceutical companies and regulatory authorities.
Speaker听 2) Dr. Anil Argarwal – Head of Medicinal Chemistry
Anil is a distinguished medicinal chemist with over 17 years of experience specializing in early drug discovery across various
therapeutic areas including Oncology, Neuroscience, anti-infectives, and metabolic diseases.听
A PhD graduate from the University of Leeds, Anil has contributed
significantly to the field, notably as a coinventor of two clinical-stage molecules:
ALK5i – PF 06952229 (Pfizer) and CDK 2,4,6 inhibitor – NUV-422 (Nuvation Bio), both currently in Phase-I trials.听
His recent work includes leading over ten drug discovery projects, advancing two clinical candidates, and numerous lead molecules in areas such as oncology and liver disease.听
Notably, a molecular glue has been nominated for further development with Anil credited as an inventor. His expertise extends to optimizing lead molecules through structure-activity relationship analysis, greatly enhancing project outcomes and organizational growth.
Any questions before our webinar?
contact us in advance to arrange a personal meeting
Medicinal chemistry
Drug Discovery
性视界鈥� international and multidisciplinary team has more than 180 years of pharmaceutical R&D experience. Collectively as a team, we worked on more than 120 biomolecular鈥�
Custom chemical services
Custom Synthesis
We support our customers by providing first kg quantities of fine and specialty chemicals, cost reduction of existing syntheses, streamlining chemical processes considering鈥�
Looks interesting?
As a leading CRO in Europe, 性视界 provides comprehensive drug discovery chemistry services for large Pharma and Biotech corporations as well as for Research Institutes and Academia
Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations and, despite challenges, bridge very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project.